Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 6991 participants.

Also called NCT01897532

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 6,991 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01897532
  • EudraCT 2011-004148-23
Other papers using this trial's data
  • Effect of Linagliptin on Cognitive Performance in Patients With Type 2 Diabetes and Cardiorenal Comorbidities: The CARMELINA Randomized Trial Diabetes care, 2019-10 DOI, PubMed 31399442
  • Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial JAMA, 2019-01-01 DOI, PubMed 30418475, PMC6583576 Not in the PMC Open Access subset.
  • Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial Diabetes care, 2020-08 DOI, PubMed 32444457, PMC7372065 In the PMC Open Access subset under a licence that is not Creative Commons.
  • Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA Circulation, 2019-01-15 DOI, PubMed 30586723

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Germany, Hungary, Israel, Japan, Malaysia, Mexico, Netherlands, Poland, Portugal, Romania, Russia, South Africa, South Korea, Spain, Taiwan, Ukraine, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01897532. Randomized; double masking; primary purpose treatment. Start 2013-07-10 (actual); primary completion 2018-01-18 (actual). Results posted on 2019-01-25.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Placebo
Intervention (Drug)
Linagliptin
Lead sponsor
Boehringer Ingelheim (class: industry)
Collaborator
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct01897532
Content hash
cfe1bd91fff8b2f93ab732d42007b5636494d73b1bc2686fda9089fe57c57842